Cognition Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cognition Therapeutics's estimated annual revenue is currently $3.5M per year.
- Cognition Therapeutics's estimated revenue per employee is $77,500
- Cognition Therapeutics's total funding is $36M.
Employee Data
- Cognition Therapeutics has 45 Employees.
- Cognition Therapeutics grew their employee count by 5% last year.
Cognition Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Chief Medical Officer and Head R&D | Reveal Email/Phone |
4 | Head Clinical Operations | Reveal Email/Phone |
5 | VP, Research | Reveal Email/Phone |
6 | Chief Medical Officer, Head R&D | Reveal Email/Phone |
7 | Director, Program Management | Reveal Email/Phone |
8 | Executive Director Pharmacology | Reveal Email/Phone |
9 | Executive Director, R&D Operations | Reveal Email/Phone |
10 | Associate Director Clinical Operations | Reveal Email/Phone |
Cognition Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $4M | 26 | 13% | N/A | N/A |
#3 | $0.9M | 6 | -14% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $10.9M | 70 | 3% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4M | 26 | -16% | N/A | N/A |
#8 | $1.7M | 11 | 22% | N/A | N/A |
#9 | $7.6M | 49 | 2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Cognition Therapeutics?
Cognition Therapeutics, Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer\'s disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large class of disease targets, and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses and proprietary medicinal chemistry that insures novel, high quality small-molecule drug candidates.
keywords:N/A
$36M
Total Funding
45
Number of Employees
$3.5M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cognition Therapeutics News
Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference ... April 25, 2022 08:00 ET |...
Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference. April 06, 2022 07:30 ET | Source: Cognition...
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update. March 30, 2022 07:00 ET | Source: Cognition Therapeutics,...
Sofia portfolio company Cognition Therapeutics awarded $75.8M in competitive grant process, to study efficacy of its technology with early Alzheimer’s patients New York, June 08, 2020 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protectio ...
Investigating Quantitative EEG as Biomarker of Patient Response to Treatment in Future Efficacy Studies Pittsburgh, PA, July 09, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheime ...
Other Companies in Pittsburgh
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 45 | 5% | N/A |
#2 | $6.5M | 45 | 2% | N/A |
#3 | $11.9M | 45 | 29% | N/A |
#4 | $5.2M | 45 | N/A | N/A |
#5 | $11.9M | 45 | 0% | N/A |